Losortan Potassium Tablet, Film Coated
Product Images NDC 68788-8639

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losortan Potassium (NDC 68788-8639). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losapotatab1 (6cc1d73f 0d63 43bc A54c 6c2295338016 01)

Chemical structure diagram of Losartan Potassium showing its molecular composition and arrangement, including potassium ion, chlorine, and multiple ring structures.*

FDA Label Image

Losapotatab2 (6cc1d73f 0d63 43bc A54c 6c2295338016 02)

A line chart comparing the percentage of patients with primary endpoint events over 66 study months for Losartan Potassium and Atenolol. The x-axis represents study months (0 to 66), and the y-axis shows the percentage of patients with primary endpoints (0% to 16%). The chart shows adjusted risk reduction of 13% with p=0.021 for Losartan Potassium compared to Atenolol.*

FDA Label Image

Losapotatab3 (6cc1d73f 0d63 43bc A54c 6c2295338016 03)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over a study period of 66 months for Atenolol (dashed line) and Losartan Potassium (solid line). The graph indicates that Losartan Potassium has a lower percentage of such patients, showing an adjusted risk reduction of 25% with a p-value of 0.001.*

FDA Label Image

Losapotatab (6cc1d73f 0d63 43bc A54c 6c2295338016 04)

A forest plot chart comparing Losartan Potassium and Atenolol event rates in patients. The chart shows hazard ratios with 95% confidence intervals for primary composite outcomes and stroke (fatal/non-fatal), stratified by age, gender, race, history of ischemic heart disease (ISH), diabetes status, and cardiovascular disease history. The chart indicates whether outcomes favor Losartan-K or Atenolol based on hazard ratios.*

FDA Label Image

Losapotatab5 (6cc1d73f 0d63 43bc A54c 6c2295338016 05)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium Tablet (solid line) and placebo (dotted line). It shows a 16.1% risk reduction with Losartan Potassium, with p=0.022, indicating statistical significance.*

FDA Label Image

Losartan Potassium Tab Usp 25mg (6cc1d73f 0d63 43bc A54c 6c2295338016 06)

Packaging label for Losartan Potassium Tab USP 25 mg tablets. The label includes directions in English and Spanish, a barcode, a QR code, and mentions Zydus Lifesciences Ltd. as the manufacturer. The label cautions against transfer of the drug and provides storage instructions. The product is film-coated and prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.